These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. Kuter DJ; Allen LF Br J Haematol; 2018 Nov; 183(3):466-478. PubMed ID: 30203841 [TBL] [Abstract][Full Text] [Related]
23. Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia. Terrault N; Chen YC; Izumi N; Kayali Z; Mitrut P; Tak WY; Allen LF; Hassanein T Gastroenterology; 2018 Sep; 155(3):705-718. PubMed ID: 29778606 [TBL] [Abstract][Full Text] [Related]
24. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis. Yang R; Lin L; Yao H; Ji O; Shen Q Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482 [TBL] [Abstract][Full Text] [Related]
26. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura. Gernsheimer TB Hematology Am Soc Hematol Educ Program; 2008; ():219-26. PubMed ID: 19074086 [TBL] [Abstract][Full Text] [Related]
28. Avatrombopag: First Global Approval. Shirley M Drugs; 2018 Jul; 78(11):1163-1168. PubMed ID: 29995177 [TBL] [Abstract][Full Text] [Related]
29. Thrombopoietin-receptor agonists in haematological disorders: the Danish experience. Gudbrandsdottir S; Frederiksen H; Hasselbalch H Platelets; 2012; 23(6):423-9. PubMed ID: 22185370 [TBL] [Abstract][Full Text] [Related]
30. Avatrombopag Effectively Maintained Platelet Counts in a Patient with Immune Thrombocytopenia Who Was Intolerant to Tyrosine Kinase Inhibitor Therapy. Maitland HS Am J Case Rep; 2021 Dec; 22():e933788. PubMed ID: 34862358 [TBL] [Abstract][Full Text] [Related]
31. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag. Tarantino MD; Fogarty PF; Shah P; Brainsky A Platelets; 2015; 26(1):93-6. PubMed ID: 24433306 [TBL] [Abstract][Full Text] [Related]
32. Sustained remission of chronic immune thrombocytopenia after discontinuation of treatment with thrombopoietin-receptor agonists in adults. Červinek L; Mayer J; Doubek M Int J Hematol; 2015 Jul; 102(1):7-11. PubMed ID: 25833724 [TBL] [Abstract][Full Text] [Related]
33. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice. Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925 [TBL] [Abstract][Full Text] [Related]
34. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura. Kuter DJ Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568 [TBL] [Abstract][Full Text] [Related]
35. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview. Vibor M; Rogulj IM; Ostojic SK Cardiovasc Hematol Disord Drug Targets; 2017 Jul; 17(1):38-51. PubMed ID: 28034281 [TBL] [Abstract][Full Text] [Related]
36. Eltrombopag: an oral thrombopoietin receptor agonist for the treatment of idiopathic thrombocytopenic purpura. Zhang Y; Kolesar JM Clin Ther; 2011 Nov; 33(11):1560-76. PubMed ID: 22054810 [TBL] [Abstract][Full Text] [Related]
37. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of thrombopoietin receptor agonists in children with chronic immune thrombocytopenic purpura: meta-analysis. Tumaini Massaro J; Chen Y; Ke Z Platelets; 2019; 30(7):828-835. PubMed ID: 30810479 [TBL] [Abstract][Full Text] [Related]
39. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484 [TBL] [Abstract][Full Text] [Related]